NOCIL Starts Trial Production for Dahej Expansion, ₹250 Cr Capex

CHEMICALS
Whalesbook Corporate News Logo
AuthorAarav Shah|Published at:
NOCIL Starts Trial Production for Dahej Expansion, ₹250 Cr Capex
Overview

NOCIL Ltd has started trial batches for rubber chemicals at its ₹250 crore Dahej expansion project. This step signals readiness for commercial production, pending customer approvals, and marks progress in the company's growth plans.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

NOCIL's Dahej Expansion Moves to Trial Production

NOCIL Limited announced today that its significant capital expenditure project at Dahej, Gujarat, has begun trial runs. The company is now producing test batches of rubber chemicals as part of an expansion plan with a total investment of up to ₹250 crore.

Today's Announcement

The company has successfully initiated trial batch production of rubber chemicals at its Dahej facility. This expansion is part of a larger project with a total expenditure not exceeding ₹250.00 crore.

The immediate next step involves sending samples from these trial runs to customers for their approval. NOCIL will officially notify the market once commercial production for the expanded capacity begins.

What This Means for NOCIL

This development marks an important step, moving the expansion project from the construction phase to being ready for operation. Successful trial runs and customer approvals are necessary before commercial production can start, which is expected to increase NOCIL's output and sales.

Company Background

NOCIL is India's largest manufacturer of rubber chemicals, supplying the tyre and rubber sectors. The company has been investing in expanding its Dahej plant. In March 2026, its board approved a ₹130 crore capital expenditure for this expansion, targeting completion by the first half of fiscal year 2028. Today's update confirms the project is progressing, with the total expenditure now capped at ₹250 crore and trial production underway.

Next Steps and Impact

  • Increased production capacity for rubber chemicals is expected soon.
  • The company is getting closer to growing its market share and sales.
  • Operational readiness is being tested through trial batches.
  • Successful customer approvals will open the door for commercial sales.
  • Shareholders can track the progress of a key growth project.

Potential Risks

Despite the progress, NOCIL faces investor concerns due to its recent financial performance. Analysts have issued 'Strong Sell' ratings, citing five consecutive quarters of losses and underperformance compared to market benchmarks. These financial challenges could affect investor sentiment.

Competitive Landscape

NOCIL competes with players such as Lanxess India Pvt. Ltd., PMC Rubber Chemicals India Pvt. Ltd., Yasho Industries Pvt. Ltd., and Swarup Chemicals Pvt. Ltd., among others.

Recent Financials

  • For the third quarter of fiscal year 2026, consolidated revenue was ₹315.84 crore.
  • Consolidated net profit for Q3 FY26 was ₹9.25 crore, with a net profit margin of 2.87%.
  • Working capital days increased over the past three years, reaching 194 days.

What to Watch For

  • Customer approval of the trial batch samples.
  • The formal announcement of commercial production commencement.
  • Future financial results that reflect the impact of the expanded capacity.
  • Management comments on the demand outlook and market share.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.